Ascenta Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Santi TherapeuticsDec 2025SEC filingmedium confidence
BiotechWaltham, US
Joshua Resnick(Director)David Grayzel(Director)Milind Deshpande(Executive Officer, Director)Simon Read(Director)
Board seatLorence Kim· per SEC Form D · $120.1M raise · filed Dec 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.